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Abstract: In this work three DNA-chitosan nanoparticle formulations (Np), differing in the 
molecular weight (MW; 150 kDa, 400 kDa, and 600 kDa) of the polysaccharide, were prepared 
and administered by two different administration routes: the hydrodynamics-based procedure 
and the intraduodenal injection. After the hydrodynamic injection, DNA-chitosan nanoparticles 
were predominantly accumulated in the liver, where the transgene was expressed during at least 
105 days. No signiﬁ cant inﬂ uence of MW was observed on the levels of luciferase expression. 
The curves of bioluminescence versus time obtained using the charge-coupled device (CCD) 
camera were described and divided in three phases: (i) the initial phase, (ii) the sustained 
release step and (iii) the decline phase (promotor inactivation, immunological and physiological 
processes). From these curves, which describe the transgene expression proﬁ le, the behavior of 
the different formulations as gene delivery systems was characterized. Therefore, the following 
parameters such as C
max
 (maximum level of detected bioluminescence), AUC (area under the 
bioluminescence-time curve) and MET (mean time of the transgene expression) were calculated. 
This approach offers the possibility of studying and comparing transgene expression kinetics 
among a wide variety of gene delivery systems. Finally, the intraduodenal administration of 
naked DNA permitted the gene transfer in a dose dependent manner quantiﬁ able with the CCD 
camera within 3 days. Nevertheless, the same administration procedure of the three formulations 
did not improve the levels of transgene expression obtained with naked DNA. This fact could 
be explained by the rapid physiological turn-over of enterocytes and by the ability of chitosan 
nanoparticles to control the DNA release.
Keywords: chitosan, nanoparticles, gene delivery, hydrodynamics-based procedure, 
bioluminescence, intestine
Introduction
Chitosan is a partially deacetylated polymer of N-acetyl glucosamine. It is usually 
prepared from chitin [(1→ 4)-2-acetamido-2-deoxy-beta-D-glucan], the second most 
universally abundant biopolymer after cellulose. The presence of amino groups on 
chitosan backbone confers a high positive charge density dependent on its deacetylation 
degree (Illum et al 1994), and makes it behave as a polycation at acidic and neutral 
pH (Schipper et al 1996). Many chitosans of different molecular weights and degrees 
of deacetylation are commercially available, and their low manufacturing costs 
render their use attractive. These cationic polymers can efﬁ ciently condense plasmid 
DNA permitting its protection during the intracellular transport (Dunlap et al 1997). 
Furthermore, through their biodegradation, polymers can control and modulate the 
release of the plasmid DNA and, thus, prolong and sustain the expression of the 
encoded protein.
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DNA-chitosan nanoparticles were ﬁ rst described as a 
non-viral delivery system for plasmids in 1995 (Mumper 
et al 1995). Several promising studies have been reported 
describing the use of chitosans in animal models. Following 
topical application of DNA-chitosan nanoparticles, 
transgene expression was detected in skin with signiﬁ cant 
levels of antigen-speciﬁ c IgG in blood (Cui et al 2001). 
After intratracheal administration, Koping-Hoggard and 
colleagues (2001) obtained a mid-airways distribution of 
the DNA-chitosan complexes, where transgene expression 
was observed in virtually every epithelial cells. On the other 
hand, the major success of this nanoparticulate system has 
been to open a new modality of administration to gene 
therapy that cannot be performed by another gene delivery 
system, viral included: the oral gene therapy. Beneﬁ ting 
from chitosan mucoadhesive properties (Janes et al 2001; 
Kato et al 2003), therapeutic approaches with DNA-chitosan 
based vaccines have been applied successfully, offering a 
new immunoprophylactic strategy for oral allergen-gene 
immunization (Roy et al 1999; Chew et al 2003).
However, levels of transgene expression remain critical 
for many therapeutic applications. A few years ago, a new 
way of administering naked DNA was developed: the 
hydrodynamics-based procedure (Liu et al 1999; Zhang 
et al 1999). This administration procedure induces very high 
levels and long term transgene expression in the liver. For 
this reason it has been widely used to evaluate a number of 
aspects including the therapeutic activity of determined genes 
(Liu and Knapp 2001), the analysis of regulatory functions 
of DNA sequences (Kramer et al 2003), and the design of 
RNAs interference (RNAi) used to silence the expression of 
targeted genes (Song et al 2003).
Despite the lack of information regarding the mechanisms 
of the hydrodynamics-based procedure, taking advantage of 
the quantiﬁ cation of a long term transgene expression allows 
the estimation of the kinetic parameters leading to a better 
understanding of the behavior of the gene delivery systems 
in vivo. The calculation of parameters such as area under 
the bioluminescence-time curve (AUC) results in valuable 
information for comparative studies (Koping-Hoggard 
et al 2004).
In the present report, following the physicochemical 
characterization of the different DNA-chitosan formulations 
(150, 400, and 600 kDa), the effect of chitosan molecular 
weight (MW) on the levels of transgene expression was ﬁ rst 
analyzed after hydrodynamic injection. Then the kinetic 
parameters of the different transgene expressions were 
calculated. In a second step, we visualized and quantiﬁ ed the 
ability of the three formulations to transduce the enterocyte 
monolayer over time after intraduodenal administration 
in mice.
Materials and methods
Materials
Chitosans were purchased from Fluka (Sigma-Aldrich, 
St. Louis, MO, USA) in MWs of 150, 400, and 600 kDa and 
85% deacetylation degree. The plasmid pEGFP-N1 (4.7 kbp) 
encoding the green ﬂ uorescent protein (GFP) was obtained 
from Clontech Laboratories Inc (Palo Alto, CA, USA), and 
the plasmid pX
2
-Luc (6.15 kbp) encoding the luciferase 
under the control of CMV promotor was kindly provided by 
Dr Novo (University of Navarra, Pamplona, Spain). Plasmids 
were puriﬁ ed with the QIAﬁ lter plasmid Giga kit that was 
purchased from Qiagen (Mississauga, ON, Canada).
D-luciferin was obtained from Xenogen (Alameda, 
CA, USA), DNAse I from Invitrogen (Barcelona, Spain), 
PicoGreen assay from Molecular Probes (Leiden, The 
Netherlands), and the chitosanase from Roche Farma 
(Madrid, Spain). OCT compound was purchased from 
Tissue-Tek (Zoeterwoude, The Netherlands). The chemical 
reagents, such as acetic acid glacial (99.5%), ethanol, and 
NaOH were purchased from PANREAC (Madrid, Spain). 
All other chemicals used were of reagent grade and obtained 
from Merck (Darmstadt, Germany).
Preparation of DNA-chitosan 
nanoparticles
DNA-chitosan nanoparticles were performed as previously 
described by Mao and colleagues (2001). The three different 
chitosans were dissolved in 1% acetic acid solution under gentle 
heating to form a 0.5% (w/v) stock solution of each polysac-
charide. For the preparation of nanoparticles, stock solutions 
were diluted to 0.02% chitosan (w/v) with 5 mM of sodium 
acetate and the pH adjusted to 5.5 with NaOH 2M. After, 
a DNA solution (100 μg/ml) in 25 mM sodium sulfate was 
prepared. Both solutions were heated at 55 °C, mixed together 
and vortexed during 20 seconds. This mixture containing the 
nanoparticles was used without any further modiﬁ cation.
Physicochemical characterization 
of the nanoparticles
Particle size, zeta potential, and morphology
The size and zeta potential of the nanoparticles were 
measured by photon correlation spectroscopy and laser 
Doppler anemometry respectively, using a Zetamaster 
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analyser system (Malvern Instruments, Southborough, 
MA, USA). Size measurements were performed at 25 °C at 
a 90° scattering angle, and each measurement was recorded 
during 90s. The mean hydrodynamic diameter was generated 
by cumulative analysis. The zeta potential measurements 
were performed with an aqueous dip cell in automatic 
mode.
Moreover, the morphology and size of the DNA-chitosan 
nanoparticles were examined by scanning electron 
microscopy (SEM) in a Zeiss DSM-940A digital scanning 
electron microscope (Oberkochen, Germany).
DNA loading effi cacy
Following synthesis, 200 μl of a dispersion of DNA-chitosan 
nanoparticles were centrifuged at 25,000 rpm during 30 min 
in a 3K30 centrifuge (rotor 12154-H, Sigma). Unbound 
DNA fraction in the supernatant (100 μl of the upper phase) 
was determined with the PicoGreen assay according to the 
manufacturer’s procedure. The ﬂ uorescence was measured 
in a Tecan GENios microplate reader (Barcelona, Spain) at 
excitation and emission wavelengths of 485 and 535 nm, 
respectively. The DNA loading efﬁ ciency was calculated as 
the ratio between the bound DNA and the total DNA amount 
used to prepare nanoparticles.
In vivo transgene expression 
monitorization and in situ localization
Hydrodynamic injection of DNA-chitosan 
nanoparticles
These studies were performed in compliance with the 
regulations of the responsible committee of the University 
of Navarra in line with the European legislation on animal 
experiments (86/609/EU).
Female Balb/c mice 6–8 weeks old (Harland, Barcelona, 
Spain), were injected via the tail vein in a volume equivalent 
to 10% of the body weight in 5–8s (containing 20 μg of DNA) 
according to the previously published procedure (Liu et al 
1999). Saline was used as a carrier solution for injection.
Intraduodenal administration of DNA-chitosan 
nanoparticles
An aqueous suspension containing 50 μg DNA loaded in 
chitosan nanoparticles was administered in the upper small 
intestine of mice that had been previously fasted overnight. 
In brief, this procedure involved inhalatory anesthetizing 
the animal, opening the abdomen and locating the region 
of the intestine tract for direct administration into the 
intestinal lumen.
Inhalatory anesthesia was performed by placing the mice 
in an induction chamber to which 4% isoﬂ urane (Forane, 
Abbott Laboratories, Madrid, Spain) in a continuous oxygen 
ﬂ ow of 3 l/min was directed (Isoﬂ urane Vaporizer, Medical 
supplier and services international limited, Barcelona, 
Spain). Two to three minutes later, the inspired isoﬂ urane 
concentration was reduced to 2%–2.5%.
Transgene expression monitorization and localization
All mice were imaged using a cooled CCD camera (Xenogen 
IVIS, Alameda, CA, USA). The mice were previously 
anesthetized (ketamine-xylazine, 10:1) and immediately 
after, 100 μl of D-luciferin (30 mg/ml) was injected 
ip, The animals were placed in a light-light chamber, and 
a gray scale reference image was obtained under low-level 
illumination. Photons emitted from cells expressing the 
luciferase protein in the mice were collected for a period of 
time (1 sec to 5 min). Bioluminescence levels were integrated 
in region of interest (ROI) drawn by hand around biolumines-
cence zones corresponding to the liver or the gastrointestinal 
tract. Background bioluminescence was subtracted according 
to values obtained in ROI drawn on untreated control animals. 
The gray scale photographic images and bioluminescence 
color images were superimposed and analyzed using the 
LIVINGIMAGE v.2.11 software overlay (Xenogen) and 
IGOR image analysis software (V. 4.02 A, WaveMetrics, 
Lake Oswego, OR, USA).
In order to localize the cells expressing the transgene 
(GFP) in treated mice, sections of the proximal and median 
regions of the small intestine were collected and placed in 
OCT 24 h post administration. The frozen sections of the 
different regions of the small intestine collected were viewed 
and pictured with a ﬂ uorescence microscope ECLIPSE E800 
(Nikon, Madrid, Spain).
Determination of the transgene 
expression kinetic parameters
After monitorization and quantification of transgene 
expression with the CCD camera, transgene expression 
was plotted versus time. From these curves, the following 
parameters describing the levels of transgene expression were 
calculated: E
max,
 t
1/2
 Ke, Ke, MET (mean time of the transgene 
expression [relative duration]), and AUC. C
max
 was deﬁ ned 
as the maximum level of detected bioluminescence during 
the transgene expressions, whereas Ke is a constant related 
to the rate at which the DNA is expressed in the organism; 
t
1/2
 Ke was considered as the transgene expression halftime in 
the body. Both t
1/2
 Ke, and Ke were calculated using data for 
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the elimination phase. AUC was evaluated by the trapezoidal 
rule up to which denoted the last sampling point. In addition, 
MET has been calculated as follows:
 
MET
AUC Photons s days
Auc Photons s days
=
( ) ×⎡⎣ ⎤⎦
( ) ×⎡⎣ ⎤⎦
/
/
2
 
(1)
in which AUMC is the area under the ﬁ rst moment of the curve. 
Both parameters were approximated by the trapezoidal rule and 
extrapolated to inﬁ nity. In addition, AUC was accepted if at 
least 80% of its value was incorporated by AUC (0−tz).
All the parameters were calculated using the WINNONLIN 
1.5 software (Pharsight Corp, Mountain View, CA, USA).
Statistical method
The Mann–Whitney U-test was performed on the transgene 
expression parameters to determine statistical signiﬁ cance. 
P  0.05 was considered to be signiﬁ cant, and P  0.01 
very signiﬁ cant.
Results and discussion
Characterisation of nanoparticles
Table 1 summarizes the main physico-chemical characteristics 
of the resulting DNA-chitosan nanoparticles prepared with 
a ratio N/P of 3.3 (Mao et al 2001). In all cases, the size of 
the resulting particles was close to 200 nm, although the use 
of chitosan with higher molecular weight (MW) slightly 
increases the size of the resulting carriers. The particles were 
positively charged and no remarkable inﬂ uence of chitosans 
MW was observed.
The quantiﬁ cation of DNA loaded in nanoparticles was 
carried out by PicoGreen assay. As shown in Table 1, the pre-
parative process appeared to be highly efﬁ cient to induce the 
DNA condensation with the polysaccharide. Thus, more than 
95% of the DNA was found to be associated with the three 
molecules of chitosan used.
SEM analysis revealed that DNA-loaded chitosan 
nanoparticles with a size of about 200 nm presented a 
fairly spherical shape with some irregularities (Figure 1). 
These results were similar to those obtained by photon 
correlation spectroscopy and showed a homogeneous size 
distribution.
In vitro release studies
The next objective of our study was to evaluate the integrity 
of DNA after the preparative process, its release from 
the chitosan nanoparticles as well as the protection offered 
by these carriers to the loaded plasmid. Therefore, gel 
electrophoresis experiments were performed (Figure 2). 
Loaded DNA-chitosan nanoparticles displayed a pattern 
of bands co-localized with the loading well, meaning that 
encapsulated DNA was unable to migrate into the gel 
due to the strong interactions with the different chitosans 
(Figure 2A; Lanes 4, 8, and 12). This ionic interaction 
was independent from the molecular weight of the 
polysaccharide. The protection of DNA was veriﬁ ed with 
DNAse I as model enzyme. Naked DNA showed a complete 
degradation (Figure 2A; lane 3), whereas encapsulated DNA 
was preserved (at the concentration used) into the loading 
wells without any longer migration (Figure 2A; lanes 5, 9, 
and 13). Furthermore, when nanoparticles were digested with 
chitosanase, the released DNA displayed the same electro-
phoretic migration pattern as the naked DNA (Figure 2A; 
lanes 6, 10, 14, and 2). This result confirmed that the 
preparative process of nanoparticles preserved the integrity 
of DNA. This result agrees well with previous observations 
reported by Mao and colleagues (2001). To reinforce the fact 
that the release of DNA can be achieved by charge interac-
tion disruption, nanoparticles were incubated with either 
NaOH or FBS. In the ﬁ rst case, the released DNA showed 
a retarded electrophoretic mobility into the gel, indicating 
that interaction disruption in our experimental conditions 
were only partial and chitosan molecules remained bound 
Table 1 Physicochemical characteristics of the DNA-chitosan nanoparticles. (pLuc: plasmid encoding for luciferase, pEGFP: plasmid 
encoding for GFP). Experimental conditions: ratio N/P of 3.3. Data express the mean ± standard deviation (n = 3)
Batch Size (nm) Zeta potential (mV) DNA loading (%)
pLuc-Np 150 194 ± 14 14.3 ± 0.8 96 ± 4
pLuc-Np 400 210 ± 18 13.7 ± 2.7 96 ± 3
pLuc-Np 600 235 ± 12 12.9 ± 3.6 97 ± 3
pEGFP-Np 150 182 ± 13 8.9 ± 5.1 96 ± 3
pEGFP-Np 400 181 ± 8 10.5 ± 1.5 96 ± 4
pEGFP-Np 600 227 ± 16 16.1 ± 4.2 97 ± 2
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to DNA (Figure 2A; lanes 7, 11, and 15). In the second case, 
the incubation between nanoparticles and FBS for 2 h led to 
a partial release of DNA with an enhanced electrophoretic 
mobility (Figure 2B). These results point out the strong 
interaction between DNA and chitosan by means of ionic 
interactions and conﬁ rmed the data described by Liu and 
colleagues (2005).
Hydrodynamic administration 
of DNA-chitosan nanoparticles
The hydrodynamics-based procedure allows high levels 
of transgene expression in the liver, and is therefore an 
interesting tool for investigating the behavior of the gene 
delivery in vivo. We took advantage of this administration 
procedure to follow a long term gene expression. The analysis 
of the transgene expression profiles obtained with the 
DNA-chitosan nanoparticles were used to determine the 
kinetic parameters of DNA expression.
Molecular imaging with the charge-coupled device 
(CCD) camera, using the luciferase as reporter gene permits 
the bioluminescence detection, spatial localization and its 
quantiﬁ cation over time in a sensitive and accurate manner 
(Bloquel et al 2006).
Figure 3A shows the levels of bioluminescence obtained 
in groups of animals treated with the 3 different formulations 
and the naked DNA (7 days post administration). These levels 
of luciferase expression at each time point were used to plot 
the curves of bioluminescence versus time (Figure 3B). 
With these curves, it is possible to differentiate the three 
following phases: the initial phase, the sustained release step 
and the decline phase.
In the initial phase or the transgene expression 24 h post 
administration, the plasmid expression was found to be much 
higher in the case of naked DNA than in DNA-chitosan 
nanoparticles. This observation is in agreement with 
Rosmanith and colleagues (2002) who reported important 
decreases (and even inhibition) of plasmid expressions when 
loaded in liposomes. In our case, no statistical differences 
in the levels of transgene expression were observed for the 
three types of nanoparticle formulations tested.
Mechanistically, the entrance of DNA into the hepatocytes, 
as shown by Zhang and colleagues (2004) using TEM, might 
be explained by the mechanism of hydroporation caused by the 
hydrodynamics-based procedure. The entrance effectiveness 
of the nanoparticulate systems could be discriminated by 
the dimension of the holes generated in the hepatocytes’ 
membrane. This hypothesis was conﬁ rmed by Kobayashi and 
colleagues (2004), which showed that particles with a size 
of 50 nm were delivered intracellularly, while nanoparticles 
with a size of 200 nm and 500 nm hardly entered into the 
hepatocytes and stayed pasted to the plasmatic membrane.
The second phase would be characterized by a sustained 
and prolonged expression of the transgene due to the release 
of encapsulated DNA. In fact, at day 7, marked differences of 
transgene expression still appeared between naked DNA treated 
animals and the 3 groups administered with the nanoparticle 
formulations. However, the differences in the intensities of 
bioluminescence between naked DNA and nanoparticle-treated 
animals were reduced to 3-fold while they were at 50-fold 
on day 1 (see Figure 3B). This fact can only be explained 
by a sustained release of DNA from nanoparticles located 
in liver cells. Meanwhile the hepatocytes can proceed to the 
extracellular particles endocytosis, this added expression is 
only transient (days 3–9), and could ﬁ nd an explanation by the 
phagocytosis of a great number of the injected nanoparticles 
by the Kupffer cells, implying their activation and that of the 
competent immune cells (Sebestyen et al 2006), which led to 
the disappearance of part of the bioluminescence. This phenom-
enon has already been described for lipoplexes after intravenous 
injection (Litzinger et al 1996; Nishikawa et al 2005).
The last phase would be characterized by the progressive 
silencing of the promotor CMV (Gerolami et al 2000; Aliño 
et al 2003; Nash et al 2004) and, probably to some extent, 
also due to the immune response generated by the presence of 
CpG activating motives (Hodges et al 2004) and the directed 
response against the foreign reporter protein (Chu et al 2005). 
All of these processes would start just after the initiation 
of the gene transfer. However, the maintenance of plasmid 
expressing liver cells is a fact that allows the detection of 
Figure 1 Scanning electron microscopy (SEM) of DNA-chitosan nanoparticles 
(Np400).
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the bioluminescence during more than 105 days after the 
hydrodynamic injection. This long term expression was not 
affected by the MW of chitosan used.
In order to characterize the kinetic proﬁ le of transgene 
expression, we proposed the following methodology. 
In preamble, we assumed that the detected bioluminescence 
can be related to the effective amount of luciferase expressed 
(Boquel et al 2006). Therefore, the curves describing the trans-
gene expressions of the different formulations administered by 
hydrodynamics-based procedure could be analysed to estimate 
some parameters that are able to quantify the intensity, extent 
and duration of the gene transfer phenomenon occurring in the 
liver. These parameters are: Emax, t
1/2
 Ke, Ke, AUC, and MET. 
In principle, C
max
 can be deﬁ ned as the maximum level of gene 
expression, while AUC, the amount of transgene expressed, 
would describe the intensity of the transduction phenomenon. 
Finally, MET would be able to estimate the relative duration 
of the transgene expression. For the different formulations 
tested, Table 2 summarizes all of these parameters.
Concerning C
max
, it was clear that the administration 
of naked DNA permitted to obtain a transgene expression 
which was quantiﬁ ed to be between 20- and 50-times higher 
than for DNA – chitosan formulations. On the other hand, 
by increasing the MW of chitosan to prepare nanoparticles, 
a slight increase on the C
max
 was observed. Similarly, 
AUC which quantiﬁ ed the global transgene expression 
phenomenon was found to be about 30 times higher for 
naked DNA than for DNA – chitosan formulations. On the 
contrary, MET (or the relative duration of the transgene 
expression) was found to be higher for chitosan nanopar-
ticles than for naked DNA. In fact, the use DNA – chitosan 
nanoparticles enabled us to prolong the expression of the 
transgene between 26.12 h and 35.76 h more than by using 
naked DNA.
In summary, despite initial high differences of transgene 
expression (C
max
) correlated to the mechanism of entrance 
into the hepatocytes (DNA versus formulations), a further 
compensation of global transgene expression (AUC) 
seemed to be due to the sustained controlled release (MET), 
indistinctly of the MW used.
Intraduodenal administration 
of DNA-chitosan nanoparticles
Taking advantage of the mucoadhesive properties of chitosans 
(Janes et al 2001; Kato et al 2003) several investigators 
have used the β-Galactosidase to observe the introduction 
Np  150  + FBS   (%) Np  400  + FBS   (%) Np  600  + FBS   (%)
Np Np Np20 20 2010 10 105 5 52.5 2.5 2.5
A
B
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 2 Electrophoresis of chitosan-DNA nanoparticles to determine effective encapsulation, DNAse I protection (digestion with DNAse I), plasmid integrity following 
release (digestion with chitosanase), and release after charge interaction disruption with NaOH or FBS. (A) Lanes 1 and 16: Molecular weight marker VII; Lane 2: pX2-Luc 
plasmid DNA; Lane 3: + DNAse I; Lane 4-8-12: nanoparticles composed of 150, 400 or 600 kDa chitosan respectively; Lane 5-9-13: + DNAse I; Lane 6-10-14: + chitosanase; 
Lane 7-11-15: + NaOH. (B) Nanoparticles composed of 150, 400, or 600 kDa chitosan incubated 2 h (37 °C) with FBS at untreated 20%, 10%, 5%, and 2.5%, respectively.
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of a foreign reporter gene in the intestinal tract of mice (Roy 
et al 1999; Chen et al 2004). However, the β-Galactosidase is 
largely expressed in the intestine due to its bacterial origin and 
shouldn’t be therefore considered as an appropriate reporter 
gene for the gastrointestinal tract. In the present study, we have 
chosen two different foreign transgenes: the green ﬂ uorescent 
protein (GFP) and the luciferase (Luc) to contrast the results 
previously reported. The DNA-chitosan nanoparticles were 
administered directly in the upper part of the duodenum, 
avoiding any acidic denaturation after the stomach passage 
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Figure 3 (A) Bioluminescent imaging of hepatic luciferase expression in living mice using a cooled CCD camera. The fi gure shows the mice 7 days after the hydrodynamic 
injection. (A1) Animals treated with naked DNA, (A2) Np150, (A3) Np400 and (A4) Np600. (B) Evolution of the transgene expression (in bioluminescence units) versus 
time. In the upper right hand of the fi gure, time course of the transgene expression is represented from day 0 to day 7.
Notes: Data express the mean ± standard deviation (n = 3).
Table 2 Kinetic parameters of transgene expression obtained for the different formulations tested. Data express the mean ± standard 
deviation (n = 3)
pLuc Cmax Ke (days−1) t1/2 Ke (days) AUC (Photons/s)xdays MET (days)
Naked DNA 2.7 × 1011 ± 1.4 × 1011 0.024 ± 0.002 35.61 ± 18.45 3.8 × 1011 ± 1.2 × 1011 2.30 ± 1.17
Np150 4.6 × 109 ± 2.7 × 109 0.020 ± 0.016 29.00 ± 3.51 1.1 × 1010 ± 4.0 × 109 3.43 ± 0.40
Np400 7.7 × 109 ± 3.0 × 109 0.015 ± 0.007 45.49 ± 12.43 1.3 × 1010 ± 3.7 × 109 3.60 ± 0.65
Np600 9.8 × 109 ± 3.6 × 109 0.019 ± 0.004 36.58 ± 12.55 1.2 × 1010 ± 3.6 × 109 3.79 ± 2.08
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and allowing therefore an estimation of the full potential of 
our gene delivery systems in the intestine.
Figure 4A shows the GFP expression in two distant 
sections of the intestine (duodenum and ileum) 24 hours post 
administration of DNA loaded in Np400. These photographs 
show that our nanoparticles were able to transduce the 
enterocyte monolayer along the intestinal tract, and with 
high intensity in some sections. These data conﬁ rmed the 
great expectative projected by several studies previously 
published (Roy et al 1999; Cheng et al 2004; Guliyeva et al 
2006; MacLaughlin et al 1998).
Bioluminescence monitorized by the CCD camera gave 
some evidence regarding the intensity of the transgene expres-
sion phenomenon over time (localization and quantiﬁ cation). 
Interestingly, after direct injection of naked DNA in the intesti-
nal lumen, transgene expression could be detected and quanti-
ﬁ ed in the intestine in a dose dependent manner (Figure 4B). 
This expression reached its maximum point at 24 h and quickly 
Proximal duodenum
Photons/s/cm2/sr
Duodenum Jejunum
24 h
24 h
A
1
1 2 3 4
5 6 7 8
2
B
2000
2200
2400
2600
2800
3000
3200
3400
3600
3800
4000
4200
4400
Figure 4 (A) Intestinal sections expressing GFP, 24 h post intraduodenal administration. (A1) 1 ml of saline as control, (A2) Np400 corresponding to a dose of 50 μg plasmid 
(pEGFP) in 1 ml of formulation. (B) Bioluminescent imaging of intestinal luciferase expression in living mice using a cooled CCD camera. (B1) 25 μg naked DNA in a volume 
of 500 μl saline; (B2) 50 μg naked DNA in a volume of 500 μl saline; (B3) 50 μg naked DNA in a volume of 1 ml saline; (B4) 100 μg naked DNA in a volume of 1 ml saline. 
(B5) Untreated animal. (B6) Amount of Np150 corresponding to 50 μg of DNA in 1 ml saline (B7) Np400 corresponding to 50 μg of DNA in 1 ml saline, and (B8) Np600 
corresponding to 50 μg of DNA in 1 ml saline.
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decreased to become hardly detectable after 72 h. These results 
correlate with the enterocytes’ lifetime determined by Ferraris 
and colleagues (1992). In the same way, the three different 
formulations were administered without any further modiﬁ -
cation after the coacervation process. Luciferase expression 
could be also followed within 3 days (Figure 5).
Unfortunately, in comparison with naked DNA, similar 
results were obtained without any improvement in the 
intestinal tract distribution and global bioluminescence 
quantification. Moreover, no statistical difference was 
noted between the 3 formulations. This phenomenon can be 
related with the very short lifetime of the mice enterocytes. 
In fact, the enterocytes would not be a good cell type target 
for such retarded sustained delivery systems as observed in 
hydrodynamics-based procedure.
Controversially, Guliyeva and colleagues (2006) were able 
to see β-Galactosidase expression in the gastrointestinal tract at 
the ﬁ fth day post oral administration using microparticles made 
of chitosan. Nevertheless, it could be explained by the fact 
that their microparticulate system could be able to reach and 
transduce the enterocytes precursors located in the intestinal 
crypts, that it could maybe also cross the epithelial barrier 
disrupting tight junctions (Smith et al 2004), or get to the Peyer 
patches via the M cells (Van Der Lubben et al 2001).
Conclusions
In conclusion, chitosan nanoparticles can be prepared by 
coacervation with a high reproducibility. No remarkable 
inﬂ uence of MW and plasmid size was observed on the 
formation and physico-chemical properties of these carriers.
After the hydrodynamic injection, DNA-chitosan nanopar-
ticles were predominantly accumulated in the liver, where the 
transgene is expressed for at least 105 days. The curves of 
luciferase expression observed with the CCD camera can be 
divided in 3 phases. Moreover, no effect of the chitosan MW 
was observed in the kinetic proﬁ les of transgene expression. 
On the other hand, the proposed methodology can permit, in 
an easy way, the calculation of kinetic parameters that char-
acterize the transgene expressions and allow further compari-
sons between wide varieties of gene delivery systems.
Finally, the intraduodenal administration of naked 
DNA allowed the gene transfer in a dose dependent manner 
quantiﬁ able within 3 days with the CCD camera. The same 
administration of the three formulations induced similar 
patterns of transgene expression without any improvement 
in the duration and intestinal distribution compared to naked 
DNA. This fact could be explained by the enterocytes’ rapid 
physiological turn-over and by signiﬁ cantly high MET that 
can be related with the ability of chitosan nanoparticles to 
sustain and prolong the release of DNA.
Acknowledgments
This research was supported by “Programa Nacional 
de Proyectos de Investigación Aplicada” (ORDEN 
PRE/621/2008). Miguel N Centelles was supported by a 
fellowship grant from the ‘Asociación de Amigos de la 
B
io
lu
m
in
es
ce
nc
e
(P
ho
to
n/
s)
120000
100000
80000
60000
40000
20000
       0
Naked
DNA
Np150 Np400 Np600
24 h
48 h
72 h
Figure 5 Evolution of the luciferase expression in the intestine over the time.
Notes: Data express the mean ± standard deviation (n = 4).
International Journal of Nanomedicine 2008:3(4)460
Centelles et al
Universidad de Navarra’. We would like to thank Prof Rafael 
Jordana, who has performed scanning electron microscopy 
of DNA-chitosan nanoparticles.
References
Alino SF, Crespo A, Dasi F. 2003. Long-term therapeutic levels of human 
alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral 
DNA. Gene Ther, 10:1672–9.
Bloquel C, Trollet C, Pradines E, et al. 2006. Optical imaging of 
luminescence for in vivo quantiﬁ cation of gene electrotransfer in mouse 
muscle and knee. BMC Biotechnol, 8:6–16.
Chen J, Yang WL, Li G, et al. 2004. Transfection of mEpo gene to intestinal 
epithelium in vivo mediated by oral delivery of chitosan-DNA 
nanoparticles. World J Gastroenterol, 10:112–16.
Chew JL, Wolfowicz CB, Mao HQ, et al. 2003. Chitosan nanoparticles 
containing plasmid DNA encoding house dust mite allergen, Der p 1 
for oral vaccination in mice. Vaccine, 21:2720–9.
Chu Q, Joseph M, Przybylska M, et al. 2005. Transient siRNA-mediated 
attenuation of liver expression from an alpha-galactosidase A plasmid 
reduces subsequent humoral immune responses to the transgene product 
in mice. Mol Ther, 12:264–73.
Cui Z, Mumper RJ. 2001. Chitosan-based nanoparticles for topical genetic 
immunization. J Control Release, 75:409–19.
Dhawan S, Singla AK, Sinha VR. 2004. Evaluation of mucoadhesive 
properties of chitosan microspheres prepared by different methods. 
AAPS PharmSciTech, 5(4):e67.
Dunlap DD, Maggi A, Soria MR, et al. 1997. Nanoscopic structure of DNA 
condensed for gene delivery. Nucleic Acids Res, 25:3095–101.
Ferraris RP, Villenas SA, Diamond J. 1992. Regulation of brush-border 
enzyme activities and enterocyte migration rates in mouse small 
intestine. Am J Physiol, 262:1047–59.
Gerolami R, Uch R, Jordier F, et al. 2000. Gene transfer to hepatocellular 
carcinoma: transduction efﬁ cacy and transgene expression kinetics by 
using retroviral and lentiviral vectors. Cancer Gene Ther, 7:1286–92.
Guliyeva U, Oner F, Ozsoy S, et al. 2006. Chitosan microparticles containing 
plasmid DNA as potential oral gene delivery system. Eur J Pharm 
Biopharm, 62:17–25.
Hodges BL, Taylor KM, Joseph MF, et al. 2004. Long-term transgene 
expression from plasmid DNA gene therapy vectors is negatively 
affected by CpG dinucleotides. Mol Ther, 10:69–78.
Illum L, Farraj NF, Davis SS. 1994. Chitosan as a novel nasal delivery 
system for peptide drugs. Pharm Res, 11:1186–9.
Janes KA, Calvo P, Alonso MJ. 2001. Polysaccharide colloidal particles as 
delivery systems for macromolecules. Adv Drug Deliv Rev, 47:83–97.
Kato Y, Onishi H, Machida Y. 2003. Application of chitin and chitosan deriva-
tives in the pharmaceutical ﬁ eld. Curr Pharm Biotechnol, 4:303–9.
Kobayashi N, Hirata K, Chen S, et al. 2004. Hepatic delivery of particulates in 
the submicron range by a hydrodynamics-based procedure: implications 
for particulate gene delivery systems. J Gene Med, 6:455–63.
Koping-Hoggard M, Tubulekas I, Guan H, et al. 2001. Chitosan as a 
nonviral gene delivery system. Structure-property relationships and 
characteristics compared with polyethylenimine in vitro and after lung 
administration in vivo. Gene Ther, 8:1108–21.
Koping-Hoggard M, Varum KM, Issa M, et al. 2004. Improved 
chitosan-mediated gene delivery based on easily dissociated chitosan 
polyplexes of highly deﬁ ned chitosan oligomers. Gene Ther, 11: 
1441–52.
Kramer MG, Barajas M, Razquin N, et al. 2003. In vitro and in vivo comparative 
study of chimeric liver-speciﬁ c promoters. Mol. Ther, 7:375–85.
Litzinger DC, Brown JM, Wala I, et al. 1996. Fate of cationic liposomes 
and their complex with oligonucleotide in vivo. Biochim Biophys Acta, 
1281:139–49.
Liu D, Knapp JE. 2001. Hydrodynamics-based gene delivery. Curr Opin 
Mol Ther, 3:192–97.
Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in 
animals by systemic administration of plasmid DNA. Gene Ther, 
6:1258–66.
Liu W, Sun S, Cao Z, et al. 2005. An investigation on the physicochemical 
properties of chitosan/DNA polyelectrolyte complexes. Biomaterials, 
26:2705–11.
MacLaughlin FC, Mumper RJ, Wang J, et al. 1998. Chitosan and 
depolymerized chitosan oligomers as condensing carriers for in vivo 
plasmid delivery. J Control Release, 56:259–72.
Mumper RJ, Wang JJ, Claspell JM, et al. 1995. Novel polymeric condensing 
carriers for gene delivery. Proc Int Symp Controlled Release Bioact 
Mater, 22:178–79.
Nash KL, Jamil B, Maguire J, et al. 2004. Hepatocyte-speciﬁ c gene expression 
from integrated lentiviral vectors. J Gene Med, 6:974–83.
Nishikawa M, Takakura Y, Hashida M. 2005. Pharmacokinetics of plasmid 
DNA-based non-viral gene medicine. Adv Genet, 53:47–68.
Rossmanith W, Chabicovsky M, Herkner K, et al. 2002. Cellular gene 
dose and kinetics of gene expression in mouse livers transfected 
by high-volume tail-vein injection of naked DNA. DNA Cell Biol, 
21:847–53.
Roy K, Mao HQ, Huang SK, et al. 1999. Oral gene delivery with 
chitosan-DNA nanoparticles generates immunologic protection in a 
murine model of peanut allergy. Nat Med, 5:387–91.
Schipper NG, Varum KM, Artursson P. 1996. Chitosans as absorption 
enhancers for poorly absorbable drugs. 1: Inﬂ uence of molecular weight 
and degree of acetylation on drug transport across human intestinal 
epithelial (Caco-2) cells. Pharm Res, 13:1686–92.
Sebestyen MG, Budker VG, Budker T, et al. 2006. Mechanism of plasmid 
delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of 
various molecules. J Gene Med, 8:852–73.
Smith J, Wood E, Dornish M. 2004. Effect of chitosan on epithelial cell 
tight junctions. Pharm Res, 21:43–9.
Song E, Lee SK, Wang J, et al. 2003. RNA interference targeting Fas protects 
mice from fulminant hepatitis. Nat Med, 9:347–51.
Van Der Lubben IM, Konings FA, Borchard G, et al. 2001. In vivo uptake of 
chitosan microparticles by murine Peyer’s patches: visualization studies 
using confocal laser scanning microscopy and immunohistochemistry. 
J Drug Target, 9:39–47.
Yang PL, Althage A, Chung J, et al. 2002. Hydrodynamic injection of viral 
DNA: a mouse model of acute hepatitis B virus infection. Proc Natl 
Acad Sci U S A, 99:13825–30.
Zhang G, Budker V, Wolff JA. 1999. High levels of foreign gene expression 
in hepatocytes after tail vein injections of naked plasmid DNA. Hum 
Gene Ther, 10:1735–7.
Zhang G, Gao X, Song YK, et al. 2004. Hydroporation as the mechanism 
of hydrodynamic delivery. Gene Ther, 11:675–82.
